124328-39-8 Usage
Description
4-aMino-3,4-dihydroisoquinolin-1(2H)-one, also known as DHIQ, is a chemical compound belonging to the class of isoquinolinone derivatives. It is a potent and selective inhibitor of the enzyme poly(ADP-ribose) polymerase-1 (PARP-1), which plays a crucial role in DNA repair and maintenance of genomic stability. DHIQ has demonstrated promising results as a PARP-1 inhibitor in preclinical studies and has also shown potential anti-inflammatory and neuroprotective effects, making it a molecule of interest for further research and development in the field of pharmacology.
Uses
Used in Pharmaceutical Industry:
4-aMino-3,4-dihydroisoquinolin-1(2H)-one is used as a PARP-1 inhibitor for its potential application in cancer therapy. By inhibiting PARP-1, DHIQ can disrupt DNA repair mechanisms in cancer cells, leading to cell death and potentially enhancing the effectiveness of other cancer treatments.
Used in Neuroprotection:
4-aMino-3,4-dihydroisoquinolin-1(2H)-one is used as a neuroprotective agent due to its demonstrated potential to protect neurons from damage and degeneration. This makes it a promising candidate for the development of treatments for neurodegenerative diseases.
Used in Anti-inflammatory Applications:
4-aMino-3,4-dihydroisoquinolin-1(2H)-one is used as an anti-inflammatory agent, leveraging its potential to modulate inflammatory processes and reduce inflammation-related damage in various conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 124328-39-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,4,3,2 and 8 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 124328-39:
(8*1)+(7*2)+(6*4)+(5*3)+(4*2)+(3*8)+(2*3)+(1*9)=108
108 % 10 = 8
So 124328-39-8 is a valid CAS Registry Number.
124328-39-8Relevant articles and documents
Design, synthesis, and biological evaluation of a series of benzo[ de ][1,7]naphthyridin-7(8 H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors
Ye, Na,Chen, Chuan-Huizi,Chen, Tiantian,Song, Zilan,He, Jin-Xue,Huan, Xia-Juan,Song, Shan-Shan,Liu, Qiufeng,Chen, Yi,Ding, Jian,Xu, Yechun,Miao, Ze-Hong,Zhang, Ao
, p. 2885 - 2903 (2013/06/04)
A series of benzo[de][1,7]naphthyridin-7(8H)-ones possessing a functionalized long-chain appendage have been designed and evaluated as novel PARP1 inhibitors. The initial effort led to the first-generation PARP1 inhibitor 26 bearing a terminal phthalazin-